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Abstract 
Treatment strategies for asthma-like symptoms are challenging with no international consensus on dose of systemic 
glucocorticoids. Despite, asthma-like symptoms remain one of the most common medical conditions seen in infants 
and preschool children. This is further complicated by limited licensed preparations and use of various 
extemporaneously prepared formulations in some countries. In Denmark, all extemporaneous formulations are 
produced according to GMP, which is different from other European countries. This retrospective cohort study 
examined the type and dose of extemporaneously prepared glucocorticoid formulations prescribed to infants and 
preschool children 0-5 years of age with acute asthma-like symptoms over a three-year period at three paediatric 
departments in the Capital Region of Denmark covering 1.8 mill inhabitants. In total 4877 patients were screened for 
eligibility. In addition, length of hospitalisation, prescribed co-medication, readmission, and adverse events were 
registered. Almost one in ten of the patients were treated with extemporaneous prednisolone. Eight different 
formulations were used interchangeably despite lack of studies supporting therapeutic equivalence between these 
formulations. Further, a higher dose did not result in shorter hospitalisation. 
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1. Introduction 
Asthma-like symptoms remain the most common medical condition seen in infants and preschool children [1]. The 
symptoms, such as wheezing, coughing and breathing difficulty, range from mild and self-limiting to severe and 
life-threatening and is one of the most frequent causes of hospital admissions in young children [2, 3]. The European 
Respiratory Society defined two pragmatic symptom-based classifications of wheezing in 2008: Episodic Viral 
Wheeze (EVW) and Multiple Trigger Wheeze (MTW) in the 0-5 year’s age group [4, 5]. These phenotypes cannot 
reliably be distinguished when the symptoms first appear, and vary comprehensively over time limiting the value in 
clinical practice [4, 6-8]. This heterogeneous group of patients is therefore diagnosed interchangeably with asthma, 
recurrent wheezing, and asthmatic bronchitis. In Denmark, the clinical diagnosis ‘asthmatic bronchitis’ is frequently 
used for patients who present with a viral-induced cough, wheezing, and dyspnoea, which diagnostically resembles 
EVW. In general, first line treatment of EVW is intermittent bronchodilator therapy, whereas the role of oral 
corticosteroids is debated [2-4, 9, 10]. As a result of limited data from randomised controlled trials and difficulties in 
applying precise diagnostic criteria, dosing recommendations, route and choice of glucocorticoids are inconsistent 
[2-4, 10]. Proposed dosing varies both internationally and nationally [2, 3]. It is important to use the lowest effective 
dose to reduce the risk of dose-dependent adverse effects [11, 12]. Especially adverse behavioural effects, e.g., 
anxiety and aggressive behaviour were found to occur more frequently with higher doses of prednisone or 
prednisolone [13].  
 
In Denmark, the licensed formulations of glucocorticoids are limited to oral tablet strengths inappropriate for 
children and intravenous preparations. In other EU countries, licensed oral glucocorticoid solutions for paediatric 
use are available. Instead, extemporaneous formulations are available in Denmark, manufactured under the Good 
Manufacturing Practice (GMP) regulations [14] by two specialized private pharmacies. The products are national 
formulations sold to public hospitals. Nonetheless, extemporaneous formulations often lack stability, efficacy, and 
safety studies [15]. Because of diagnostic challenges in preschool children with asthma-like symptoms and the 
extensive use of different extemporaneous prednisolone formulations, it is difficult to improve treatment strategies. 
The objective of this study was to ascertain the type and dose of extemporaneously prepared glucocorticoid 
formulations administered to children 0-5 years of age with acute asthma-like symptoms at three different paediatric 
departments in the Danish Capital Region. Further, to evaluate if the selected dose affected the length of 
hospitalisation, prescribed co-medication, readmissions, and adverse events. 
 
2. Methods 
2.1 Design and settings 
We conducted a retrospective cohort study on admitted patients or patients with an emergency visit at three 
paediatric departments at Copenhagen University Hospital Hvidovre, -Herlev and -Nordsjælland, Hillerød. All three 
hospitals were secondary hospitals with similar size reference areas in the Capital Region of Denmark. Each hospital 
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had a paediatric emergency room and treated typical paediatric diseases. The reference areas encompass a broad 
spectrum of sociodemographic populations representing families attaining all educational levels. The study was 
approved by the Institutional Data Safety Committee, the Danish Data Protection Agency (BFH-2015-089 and I-
Suite no.: 04284), and The Board for Patient Safety, Danish Health and Medicines Authority (ID: 3-3013-1457/1), 
waiving the need for patient consent. Data were retrospectively captured through chart review and extraction from 
electronic health records (EHR) from September 2016 to October 2017. 
 
2.2 Study population  
Infants and preschool children 0-5 years of age with a main diagnosis of asthma-like symptoms, defined by ICD 
(International Classifications of Diseases)-codes DJ20.9 and DJ45.9, and administered an extemporaneous 
glucocorticoid formulation were included between January 2013 and December 2015. Dispensed or administered 
doses of extemporaneous glucocorticoids were included in accordance with the Electronic Patient Medication 
Module (EPM). The treatment recommendations for oral systemic glucocorticoids for severe asthma-like symptoms 
differed in the three departments (2013-15): Hospital A: Initial dose of up to 2 mg/kg followed by 1 mg/kg for a 
total of 3 days; Hospital B and C: Initial and maintenance dose of 1 mg/kg for a total of 3 days. 
 
2.3 Data extraction variables 
Patient data were collected from the time of administration of the first dose of extemporaneous glucocorticoid 
formulation. Demographic data at baseline included the date of birth, weight, gender, diagnose: ICD codes J45.9 
(Other and unspecified asthma) or J20.9 (Acute bronchitis, unspecified), comorbidity, length of hospitalisation in 
days, and prednisolone dose and formulation. Further, co-medication on and during admission (asthma 
medication/antibiotics), culture and sensitivity results from microbiology, adverse events and defined readmissions 
were registered. Adverse events (AEs) were captured by two reviewers when it was described as an adverse event in 
the chart and coded using the current version of the Medical Dictionary for Regulatory Activities, Version 19.0 
(MedDRA MSSO, McLean, Virginia, USA). If the child was readmitted within seven days, this was regarded as a 
part of the recent admission and was excluded. 
 
2.4 Data analysis 
Continuous data were summarised as means with standard deviations or medians with range. Prednisolone doses 
were calculated as mg/kg using the dose administered at inclusion day and the body weight available in the EHR and 
EPM. The total dose dispensed or administered in the first 24 h was calculated, since the initial doses were expected 
to differ between hospitals. The estimated length of hospitalisation was the number of days calculated from the day 
where first dose prednisolone was administered to the day of discharge and an estimation of duration with symptoms 
needed to be treated in hospital. The relationship between the number of days of hospitalisation and the dose of 
extemporaneous prednisolone was estimated by a dual link Conway-Maxwell-Poisson (CMP) regression model 
where dose affected both the rate and dispersion parameters through separate log-linear models [16]. The CMP 
distribution was chosen to accommodate the under-dispersion of the observed data. The regression was adjusted for 
hospital and the significance of dose was assessed by a likelihood ratio test with two degrees of freedom. The effect 
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of hospital on dose was assessed by a permutation-based ANOVA test and 95% confidence intervals for the pair-
wise differences in means and medians, were calculated by non-parametric bootstrap using 10
5
 resamples. The 
analyses were performed using statistical software packages SAS version 9.4 and R version 3.4.3. P-values below 
5% were considered statistically significant.  
 
3. Results 
Four thousand eight hundred and seventy-seven patients were screened for eligibility. In total, 378 patients 
diagnosed with asthma-like symptoms were treated with extemporaneously glucocorticoid preparations (8%) (Figure 
1 and Table 1). Overall, they accounted for 433 admissions. Table 1 outlines the anthropometric and clinical 
characteristics of the admissions in the three hospitals by calendar-year. There were no statistically significant 
differences between the hospital populations (A, B, C). Thirty-seven percent were females. Twenty-three 
readmissions within seven days were registered at all three hospitals and excluded (Table 1).  
 
*e.g. no current weight listed in the medical records  
Figure 1: Enrolled admissions in the study, inclusion and exclusion of patients. 
 
3.1 Type of formulations and doses of extemporaneous glucocorticoids  
Eight different types of extemporaneous formulations (tablets, solutions, and suppositories) were recorded. Oral 
formulations were most frequently administered to patients in all three departments, but different oral formulations 
were used interchangeably (Figure 2). The formulations include different excipients, see Supplementary Table S2. 
4877 
• PATIENTS ASSESED FOR ELIGIBILITY 
• Diagnosed with asthma like symptoms (DJ209, DJ209A, DJ205, DJ459) or croup (DJ050, DJ040) in 2013-2015 
• Aged 0-5 years 
4237 
• Excluded patients  
 * Did not receive any prednisolone (n=3695)  * Only received licensed glucocorticoids (n=199) 
 * Data incomplete (n=78)*    * Received extemporaneous glucocortioids for other diagnoses (n=70) 
 * Treated at another hospital (n=30)   * >5 years (n=2) 
 * Extemporaneous glucocorticoids not administered (n=95) * Pneumonia as primary hospital diagnosis (n=31) 
 * ICD codes (e.g. DJ451, DJ469) not includedin this study (n=13) * Diagnosed bronchiolitis, RSV positive (n=24) 
640 
•PATIENTS RECEIVING EXTEMPORANOUS GLUCOCORTICOIDS  
 * Patients excluded diagnosed with croup (n=262)  
378 
 
•PATIENTS INCLUDED 
433 
•ADMISSIONS INCLUDED IN THIS STUDY 
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Table 1 outlines demographic data for the three different hospitals (A-C) and calendar-year (2013-2015). 
Hospital-calendar year A-2013 A-2014 A-2015 B-2013 B-2014 B-2015 C-2013 C-2014 C-2015 p-value 
Number of admissions 47 95 91 43 56 34 15 25 27 - 
Age in months* 22 ± 14 24 ± 14 25 ± 15 24 ± 14 21 ± 9 23 ± 10 18 ± 7 20 ± 11 25 ± 11 0.37 
Gender (M/F) 37/10 65/30 63/28 27/16 31/25 18/16 10/5 20/5 21/6 0.1 
Weight in kg* 12.4 ± 2.9 12.6 ± 2.8 13.4 ± 3.3 12.4 ± 2.7 12.2 ± 2.4 11.8 ± 2.3 11.2 ± 1.9 11.5 ± 3.0 12.8 ± 2.1 0.02 
Height in cm* 92 ± 6 90 ± 12 88 ± 12 87 ± 11 89 ± 9 88 ± 11 84 ± 5 82 ± 14 92 ± 8 0.77 
Length of hospitalisation in 
days* 
2.5 ± 1.0 2.2 ± 0.9 2.3 ± 0.8 1.7 ± 0.7 1.8 ± 0.7 2.0 ± 0.7 2.1 ± 1.2 2.7 ± 0.9 3.1 ± 1.4 - 
Length of hospitalisation in 
days** 
2[1;6] 2[1;5] 2[1;4] 2[1;4] 2[1;4] 2[1;4] 2[1;5] 2[1;4] 3[1;6] - 
Total dose on the day of 
inclusion in mg/kg* 
2.30 ± 0.7 2.28 ± 0.9 2.28 ± 0.9 1.27 ± 0.6 1.23 ± 0.5 1.59 ± 0.5 1.67 ± 0.8 1.63 ± 0.6 1.8 ± 1.0 - 
Number of positive 
microbiology cultures 
3 5 0 2 3 0 0 3 10 - 
Number of readmissions 
within 7 days 
1 7 4 1 3 2 1 2 2 - 
*Mean ± SD, **Median [range] 
Table 1: Demographic and clinical characteristics.
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Figure 2 shows the eight different extemporaneous formulations used in the different hospitals (A, B and C) and 
calendar year (2013-2015).  
 
The unspecified preparations are either one of the above formulations, just not assigned correctly in Electronic 
Patient Medication Module (EPM) or an extemporaneous formulation which no longer exists at the Danish market. 
Figure 2: Extemporaneous formulations by hospital and calendar-year. 
 
 
Figure 3: (A) Prednisolone dose (mg/kg) on the day of inclusion by hospital; (B) Paired difference in dosing 
between hospitals; (C) Total dose of prednisolone on the day of inclusion compared to length of hospitalisation. 
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Figure 3A shows violin plots of the distributions of doses stratified by hospital with added boxplots and mean values 
(straight lines). The percentage of patients that received exactly 1 mg/kg was 4%, 21% and 18% for Hospitals A, B 
and C respectively. For 2 mg/kg the percentages were 15%, 10% and 12% respectively. The pair-wise differences in 
doses mg/kg between Hospitals summarized through means and medians are shown in Figure 3B along with 95% 
confidence intervals. Figure 3C shows the length of hospitalisation in days and the dose of prednisolone at the day 
of inclusion in mg/kg for Hospital A, B and C along with the estimated average relationship for each hospital and 
95% point-wise confidence intervals. Jitter has been added to the length of hospitalisation solely for illustrative 
purposes. 
 
3.3 Effect of dose of prednisolone on length of hospitalisation 
The Conway-Maxwell-Poisson regression showed a significant and positive association between the length of stay 
and the total dose of extemporaneous prednisolone even when adjusting for hospital. A higher dose increased the 
expected length of stay (p<0.001), Figure 3C. The effect of hospital was included in the regression model as a 
factor-valued covariate allowed to affect both the average length of stay as well as the variance of the length of stay 
as a function of dose. To account for a potential difference in disease severity between hospital’s Paediatric Early 
Warning Scores (PEWS) were randomly collected from 20, 20 and 18 patients in 2015 from Hospital A, B and C 
respectively. PEWS is a recognized tool to detect deterioration in hospitalised children [17] and was the only 
available parameter registered in all hospitals and by same regional procedure, but only electronically available from 
January 2015. A one-way ANOVA analysis showed no difference in average PEWS score between the three 
hospitals (p=0.23). 
 
3.4 Co-medication 
In almost all (94%) admissions (409 out of 433) patients were treated with beta-2-agonists in nebulised form, as 
recommended in the guidelines, ranging from 1 to 18 doses at the day of inclusion (Supplementary Table S3). 
Ipratropium bromide was primarily used in Hospital B. In seventy-nine admissions, patients received antibiotics 
(18%), amoxicillin was used most frequently. Treatment with inhaled fluticasone varied between hospital and 
calendar-year with more patients receiving fluticasone in Hospital A. In total, fluticasone was administered in 111 
admissions (26%). 
 
3.5 Adverse events 
In total 12 AEs were captured in the medical charts from 2013-2015 i.e. agitation, leucocytosis and hyperglycaemia. 
 
4. Discussion  
Almost one in 10 children admitted with asthma-like symptoms over a three-year period were treated with 
extemporaneous prednisolone. Both 1 and 2 mg/kg were used as initial dose in Hospital A-C despite differences in 
local guidelines, most likely reflecting the severity of symptoms assessed by the prescribing physician. In total, eight 
different extemporaneous formulations were used reflecting the need for different formulations in different age 
groups and different preferences of the child. These findings are in line with a variety of unlicensed and untested 
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captopril formulations used interchangeably for children with heart failure in the UK [18]. Likewise, we found that 
oral solutions were the most used formulation, also confirmed by Lucas-Bouwman et al. [19]. However, no studies 
support the interchangeable use of various prednisolone formulations, as rate and extent of prednisolone absorption 
could vary and be dependent of the excipients used [20]. Other drawbacks of extemporaneously prepared 
formulations are limited shelf-life, safety-profile, taste etc. [21-23]. Unavailability of licensed drugs appropriate for 
children in countries with small populations makes it challenging to avoid the use of extemporaneous formulations 
[24, 25]. For example, marketed prednisolone products are available in UK, Germany, The Netherlands, France and 
Italy, interestingly with different dose recommendations for treatment of acute asthma, see supplementary Table S1. 
 
The initial dose of prednisolone varied significantly (p<0.001) between hospitals. However, treatment strategies 
included maintenance dosages that were at least twice as high as in adults. Treating children with higher doses per 
kilo is noteworthy, but may partly be explained by a higher hepatic clearance of glucocorticoids in young children, 
caused by a higher liver size relative to body weight [26]. The evidence of the superiority of any treatment regime is 
sparse in preschool children which was reflected in the inconsistency in doses administered in this study both 
between hospitals and within the same paediatric department in the same region [27].  
 
In the present study, a higher dose was associated with an increase in the expected length of stay (p<0.001). This 
could be confounding by indication, as a high initial dose may reflect severity of symptoms or a previous 
complicated medical history. For example, more patients in Hospital A received fluticasone, which may indicate 
intermittent asthma-like symptoms (MTW), which cannot be accounted for in this study. Severity of symptoms is 
included as an important factor in the assessment of wheezing in the ERS update [4] with the possibility of a more 
individual approach. Nevertheless, children with acute asthma-like symptoms despite severity might not have a 
therapeutic advantage of 2 mg/kg compared with 1 mg/kg nor shorter recovery as reported by Langton et al. [28].  
 
Adding to the heterogeneity some clinical studies suggest viral-induced wheezing is partly resistant to corticosteroid 
treatment and the specific virus causing the symptoms should be assessed [29]. In the present study available 
microbiology results for each patient were collected. Only 26 patients had a positive laryngeal sample where 
different patterns of viruses and bacteria were identified. These possible clinical infections could also explain some 
of the differences in length of stay. Notably, Farber et al. found that overprescribing of oral corticosteroids in 
children with viral respiratory infections is still ongoing [30]. In our study, children with bronchiolitis or tested 
positive for respiratory syncytial virus were excluded due to potential resistance to steroid treatment [29].  
 
Consistent with current local hospital guidelines nearly all patients received inhaled beta-2-agonists as first-line 
treatment. The 6% that did not receive beta-2-agonists, could have received inhaled saline as first-line treatment, 
which is not recorded in the EPM. The number of beta-2-agonists doses varied considerably between hospitals (i.e. 1 
to 18 doses/ 24 hr). This remains the treatment of choice, though the evidence is limited [4]. Hospital A used the 
highest doses of prednisolone but the lowest number of beta-2-agonist doses, however, that prednisolone could be 
beta-2-agonist sparring is not consistent with the findings of Langton et al. Eighteen percent received antibiotics 
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primarily beta-lactams. A study by De Boeck et al. shows that co-administration of asthma medications and 
antibiotics is very likely OR 1.90 95% [CI 0.89-1.90] [31]. The authors postulate that this finding may be due to 
respiratory tract infections treated with antibiotics despite viral origin or underlying secondary infection [31]. These 
patients were not excluded since beta-lactams have no documented effect on the duration of symptoms in contrast to 
azithromycin treatment [32]. 
 
Only a few AEs were captured i.e. agitation, leucocytosis and hyperglycaemia, which corresponds to very common 
AE’s [33]. Confounding of glucocorticoid behavioural adverse effects may arise due to the potential for co-
administered beta-2-agonists to also result in similar effects, e.g. agitation. Further, as the hospitalisation is 
relatively short, side effects may be seen at home.  
 
5. Limitations 
This study relied on correct ICD code registration. The number of patients eligible for inclusion was similar over the 
three-year period, except for Hospital B where only one third were identified in 2015. Despite several efforts, it was 
not possible to explain this variation. It might be due to shift in the ICD coding practice. Furthermore, registration of 
extemporaneous formulations is not 100% complete in EPM. The frequency may therefore be slightly 
underestimated. The length of hospitalisation was calculated in days, which may be less precise if the child was 
admitted close to midnight. Counted by hours from admission-note to discharge-note, would also be misleading due 
to delays in registration or discharging. Two researchers conducted the data collection to increase consistency. To 
assess severity, we did a random sample of the PEWS score from each hospital in 2015. However, the recording of 
the PEWS score was noted in the chart within a variable period from treatment. 
 
6. Conclusion 
Considerable variability in choice of extemporaneous prednisolone formulations for asthma-like symptoms were 
seen between Hospitals A, B and C within the same region. The initial prednisolone dose differed significantly 
between hospitals, yet a higher dose did not result in a shorter duration of hospitalisation. Studies on bioequivalence 
between formulations are lacking. In addition, studies confirming which children benefit from oral glucocorticoids 
are warranted. 
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